Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Primary Central Nervous System Lymphoma

Condition:   Primary Central Nervous System Lymphoma Interventions:   Drug: ICP-022;   Drug: Pemetrexed Sponsor:   Henan Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials